Health Care [ 3/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 26 | -0.73 Decreased by -179.23% | -0.78 Increased by +7.22% |
| Mar 30, 26 | 307.53 Increased by +69.99 K% | -1.19 Increased by +25.92 K% |
| Nov 13, 25 | -121.60 Decreased by -30.30 K% | -0.10 Decreased by -121.50 K% |
| Aug 12, 25 | -251.24 Decreased by -61.18 K% | -0.22 Decreased by -111.91 K% |
| May 7, 25 | -0.26 Increased by +42.22% | -0.21 Decreased by -25.00% |
| Mar 18, 25 | -0.44 Decreased by -12.82% | -0.31 Decreased by -43.46% |
| Nov 5, 24 | -0.40 Increased by +18.37% | -0.40 |
| Aug 8, 24 | -0.41 Increased by +8.89% | -0.42 Increased by +2.38% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -219.59 M Decreased by -575.94% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | 1.72 B Increased by +5.71 K% | Increased by +N/A% Increased by +N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -812.68 M Decreased by -2.85 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -1.57 B Decreased by -5.55 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -32.49 M Decreased by -5.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 3.69 M Decreased by -69.85% | -30.71 M Decreased by -16.95% | Decreased by -833.21% Decreased by -287.91% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -27.56 M Increased by +16.97% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -27.84 M Increased by +7.14% | Decreased by N/A% Decreased by N/A% |